
Alpine Immune Sciences (NASDAQ:ALPN) brought in sales totaling $4.53 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 12.4%, resulting in a loss of $15.17 million. Alpine Immune Sciences collected $8.52 million in revenue during Q3, but reported earnings showed a $13.49 million loss.